| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FMB.11.18 |
| P698 | PubMed publication ID | 21526943 |
| P50 | author | Sabine Pereyre | Q42319674 |
| Cécile Bébéar | Q42319677 | ||
| P2093 | author name string | Olivia Peuchant | |
| P2860 | cites work | Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance | Q24548472 |
| Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae | Q44475163 | ||
| Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance | Q46260038 | ||
| Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics | Q54681120 | ||
| Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. | Q27631119 | ||
| Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation | Q33836628 | ||
| Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas | Q33836759 | ||
| Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae | Q34352193 | ||
| Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan | Q34370748 | ||
| High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. | Q34508854 | ||
| New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections | Q34657784 | ||
| In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas | Q34722730 | ||
| Azithromycin failure in Mycoplasma genitalium urethritis | Q35792616 | ||
| Mycoplasma pneumoniae and its role as a human pathogen | Q35920629 | ||
| Mechanisms of drug resistance in Mycoplasma pneumoniae. | Q36266323 | ||
| Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia | Q36422675 | ||
| Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China | Q37190747 | ||
| Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China | Q37190781 | ||
| Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. | Q37190851 | ||
| Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia | Q37679736 | ||
| Development of multiple-locus variable-number tandem-repeat analysis for molecular typing of Mycoplasma pneumoniae | Q37855549 | ||
| First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. | Q37859031 | ||
| Atypical bacterial pneumonia and asthma risk | Q37865771 | ||
| Mycoplasma pneumoniae and asthma in children | Q37867109 | ||
| In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe | Q37871838 | ||
| Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas | Q39474505 | ||
| Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil | Q39478313 | ||
| Genomic repeats, genome plasticity and the dynamics of Mycoplasma evolution | Q39600720 | ||
| Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis | Q39653033 | ||
| Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis. | Q39658112 | ||
| Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae | Q39781041 | ||
| High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. | Q40356665 | ||
| In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. | Q40469366 | ||
| In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively | Q41092975 | ||
| Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis | Q42111895 | ||
| Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China | Q42967138 | ||
| Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates | Q43610374 | ||
| Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro | Q43760729 | ||
| Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. | Q44242565 | ||
| Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencing. | Q44261827 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycoplasma pneumoniae | Q310904 |
| antibiotic resistance | Q380775 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 423-431 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Future Microbiology | Q15759961 |
| P1476 | title | Mycoplasma pneumoniae: susceptibility and resistance to antibiotics | |
| P478 | volume | 6 |
| Q44700687 | Acquired resistance to the 16-membered macrolides tylosin and tilmicosin by Mycoplasma bovis |
| Q59073109 | Adaptation of mycoplasmas to antimicrobial agents: Acholeplasma laidlawii extracellular vesicles mediate the export of ciprofloxacin and a mutant gene related to the antibiotic target |
| Q36669885 | Antimicrobial susceptibility and molecular characterization of macrolide resistance of Mycoplasma bovis isolates from multiple provinces in China |
| Q50047524 | Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children |
| Q33723944 | Association of Mycoplasma pneumoniae infection with increased risk of asthma in children |
| Q39118434 | Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia. |
| Q93183133 | Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children |
| Q93343610 | Clinical features and seasonal variations in the prevalence of macrolide-resistant Mycoplasma pneumoniae |
| Q28547749 | Comparative "-omics" in Mycoplasma pneumoniae Clinical Isolates Reveals Key Virulence Factors |
| Q89736460 | Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children |
| Q37713512 | Comparison of the illumigene Mycoplasma DNA amplification assay and culture for detection of Mycoplasma pneumoniae |
| Q34826656 | Current and emerging Legionella diagnostics for laboratory and outbreak investigations. |
| Q40868497 | Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. |
| Q36269709 | Development of a multiplex real-time PCR assay for detection of Mycoplasma pneumoniae, Chlamydia pneumoniae and mutations associated with macrolide resistance in Mycoplasma pneumoniae from respiratory clinical specimens |
| Q37844334 | Diagnosis and antimicrobial treatment of Mycoplasma genitalium infection: sobering thoughts |
| Q37713726 | Direct detection of macrolide resistance in Mycoplasma genitalium isolates from clinical specimens from France by use of real-time PCR and melting curve analysis |
| Q37586821 | Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics |
| Q44661608 | Editorial commentary: infections due to macrolide-resistant Mycoplasma pneumoniae: now what? |
| Q37435982 | Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children |
| Q36978977 | Effects of Traditional Chinese Medicine Qinbai Qingfei Concentrated Pellet on Cellular Infectivity of Mycoplasma pneumoniae |
| Q26744683 | Epidemiology of Mycoplasma pneumoniae Infections in Japan and Therapeutic Strategies for Macrolide-Resistant M. pneumoniae |
| Q49864046 | Genotyping and macrolide resistance of Mycoplasma pneumoniae identified in children with community-acquired pneumonia in Medellín, Colombia |
| Q40448204 | In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. |
| Q41093903 | In Vitro Fractional Inhibitory Concentration (FIC) Study of Cefixime and Azithromycin Fixed Dose Combination (FDC) Against Respiratory Clinical Isolates |
| Q26752332 | Infection with and Carriage of Mycoplasma pneumoniae in Children |
| Q34899246 | Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs |
| Q91877308 | Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease |
| Q35105923 | Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China |
| Q38061407 | Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection |
| Q39424555 | Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children |
| Q43181502 | Modulation of P1 and EGF expression by Baicalin |
| Q35952824 | Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States |
| Q42692693 | Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child. |
| Q91043243 | Mutations associated with change of susceptibility to lincosamides and/or macrolides in field and laboratory-derived Mycoplasma californicum strains in Japan, and development of a rapid detection method for these mutations |
| Q34394274 | Mycoplasma Contamination of Cell Cultures: Vesicular Traffic in Bacteria and Control over Infectious Agents |
| Q64137663 | Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia |
| Q39327219 | Mycoplasma pneumoniae from the Respiratory Tract and Beyond |
| Q39174067 | Mycoplasma pneumoniae thymidine phosphorylase |
| Q26742180 | Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment |
| Q38003357 | Nasopharyngeal disease in cats: 2. Specific conditions and their management. |
| Q36965933 | No detection of macrolide-resistant Mycoplasma pneumoniae from Swedish patients, 1996-2013. |
| Q51595534 | Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. |
| Q26768548 | Potential Molecular Targets for Narrow-Spectrum Agents to Combat Mycoplasma pneumoniae Infection and Disease |
| Q39850842 | Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia |
| Q54335551 | Protective efficacy of a Mycoplasma pneumoniae P1C DNA vaccine fused with the B subunit of Escherichia coli heat-labile enterotoxin. |
| Q93055453 | Real-Time PCR and Quantitative Culture for Mycoplasma pneumoniae Load in Pharyngeal Swabs from Children at Preliminary Diagnosis and Discharge |
| Q91750487 | Relationship between Antimicrobial Susceptibility and Multilocus Sequence Type of Mycoplasma bovis Isolates and Development of a Method for Rapid Detection of Point Mutations Involved in Decreased Susceptibility to Macrolides, Lincosamides, Tetracyc |
| Q45073806 | Resident Microbiome Disruption with Antibiotics Enhances Virulence of a Colonizing Pathogen. |
| Q37847210 | Respiratory tract infections during the 2011 Mycoplasma pneumoniae epidemic |
| Q92652148 | Reverse vaccinology and subtractive genomics reveal new therapeutic targets against Mycoplasma pneumoniae: a causative agent of pneumonia |
| Q40378895 | Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila |
| Q39157514 | Risk Factors for Drug-Resistant Cap in Immunocompetent Patients |
| Q44059118 | Serological Analysis and Drug Resistance of Chlamydia pneumoniae and Mycoplasma pneumoniae in 4500 Healthy Subjects in Shenzhen, China. |
| Q39278428 | Solithromycin for the treatment of community-acquired bacterial pneumonia. |
| Q35075260 | Specific multilocus variable-number tandem-repeat analysis genotypes of Mycoplasma pneumoniae are associated with diseases severity and macrolide susceptibility |
| Q38291944 | Structural Study of MPN387, an Essential Protein for Gliding Motility of a Human-Pathogenic Bacterium, Mycoplasma pneumoniae. |
| Q35860090 | Systematic Structural Analyses of Attachment Organelle in Mycoplasma pneumoniae. |
| Q26751077 | The Evolution of Advanced Molecular Diagnostics for the Detection and Characterization of Mycoplasma pneumoniae |
| Q34305578 | The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel |
Search more.